Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875736 | 0.86 | CCNE1 (0.38) | CDK2CCNE1CDK5FDPSCCNT1 | |
| SCHEMBL27809783 | 0.83 | CDK2 (0.53) | CDK2CCNE1CDK5FDPSCCNT1 | |
| SCHEMBL2139644 | 0.82 | CDK2 (0.51) | CDK2CCNE1CDK5FDPSCCNT1 | |
| SCHEMBL2628924 | 0.82 | CDK2 (0.51) | CDK2CCNE1CDK5FDPSCCNT1 | |
| SCHEMBL5875760 | 0.80 | PSEN1 (0.38) | CDK2CCNE1CDK5FDPSCCNT1 | |
| SCHEMBL2565411 | 0.80 | CDK2 (0.50) | CDK2CCNE1CDK5FDPSCCNT1 | |
| SCHEMBL5119804 | 0.79 | PSEN1 (0.37) | CDK2CCNE1CDK5CCNT1ALDH1A1 | |
| SCHEMBL5712529 | 0.78 | PSEN1 (0.43) | CDK2CCNE1CDK5FDPSCCNT1 | |
| SCHEMBL5875558 | 0.78 | PSEN1 (0.40) | CDK2CCNE1CDK5CCNT1ALDH1A1 | |
| SCHEMBL5712486 | 0.77 | PSEN1 (0.45) | CDK2CCNE1CDK5FDPSCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | claimed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| US-20080207712-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-08-28 | — | — | US | claimed |
| US-7384968-B2 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-06-10 | — | — | US | claimed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | claimed |
| EP-1735292-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. | 2006-04-20 | — | — | US | claimed |
| JP-2006504796-A | — | — | 2006-02-09 | — | — | JP | claimed |
| WO-2005095367-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | claimed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| WO-2005095367-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | disclosed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CDK2 993/4885CCNE1 3511/4885CDK5 1119/4885 |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | APP, PARK7, IAPP | CDK2 1792/4885CCNE1 1853/4885CDK5 506/4885 |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | CDK2 3786/4885CCNE1 4870/4885CDK5 2814/4885 |
| US-20080207712-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, BACE1 | CDK2 1346/4885CCNE1 1358/4885CDK5 384/4885 |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | APP, PSEN1, BACE1 | CDK2 1346/4885CCNE1 1358/4885CDK5 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.